相关实验视频

Updated: Jun 12, 2025

A Protocol for Functional Assessment of Whole-Protein Saturation Mutagenesis Libraries Utilizing High-Throughput Sequencing

A Protocol for Functional Assessment of Whole-Protein Saturation Mutagenesis Libraries Utilizing High-Throughput Sequencing

Published on: July 3, 2016

与疾病相关的基因的和突变增强功能测试

Kaiyue Ma¹, Shushu Huang², Kenneth K Ng²

¹Department of Genetics, Yale School of Medicine, New Haven, CT, USA; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China.

|September 26, 2024

概括

这项研究引入了一种简单的,具有成本效益的称为和突变增强功能测试 (SMuRF) 的方法来解释遗传变异. SMuRF提供了对疾病基因的功能洞察,有助于变异分类和预测.

科学领域:

人类遗传学
分子生物学
基因组学

背景情况:

解释基因变异对于诊断疾病至关重要,但仍然具有挑战性.
目前的变种分析方法往往昂贵和复杂,限制了全基因组的应用.
尚未解决的变异阻碍了准确的诊断和遗传咨询.

研究的目的:

开发一个简单且具有成本效益的高分辨率变体解释框架.
提高与疾病相关的基因变异的理解.
促进研究实验室广泛实施变异对功能分析.

主要方法:

开发了和突变增强功能测试 (SMuRF).
用SMuRF对FKRP和LARGE1基因进行和突变和功能测试.
为所有编码单核酸变体生成功能分数.

主要成果:

在FKRP和LARGE1中,SMuRF成功生成了所有变体的功能分数.
功能分数有助于解决具有不确定的意义的变量.
在预测疾病严重程度和识别关键结构区域方面,SMuRF 显示出有用性.

结论:

SMuRF提供了一个具有成本效益的方法来了解疾病基因的变异功能.
该框架可以被标准研究实验室广泛实施.
SMuRF为计算预测器开发和临床变异解释提供了有价值的数据.

关键词:

具有成本效益的变体解释深度突变扫描诊断系统其他疾病遗传性疾病高通量功能测试肌肉发育不良和突变发生变量效应预测不确定的变种

更多相关视频

A Novel Saturation Mutagenesis Approach: Single Step Characterization of Regulatory Protein Binding Sites in RNA Using Phosphorothioates

A Novel Saturation Mutagenesis Approach: Single Step Characterization of Regulatory Protein Binding Sites in RNA Using Phosphorothioates

Published on: August 21, 2018

In Vivo Modeling of the Morbid Human Genome using Danio rerio

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

相关概念视频

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...